Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Nonaspirin NSAIDs and contralateral breast cancer risk

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Change in mammographic density across birth cohorts of Dutch breast cancer screening participants

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vitamin D levels and Cancer Incidence in 217.244 individuals from Primary Health Care in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Delayed two-stage breast reconstruction: The impact of radiotherapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Laboratory studies suggest that inhibition of the cyclooxygenase (COX)-2 enzymes inhibits breast cancer development. We aimed to evaluate whether postdiagnosis use of COX-2 selective or other nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of contralateral breast cancer (CBC) among Danish breast cancer patients. From the clinical database of the Danish Breast Cancer Group, we identified 52,723 women diagnosed with breast cancer between 1996 and 2012. Data on nonaspirin NSAID use, CBC and potential confounding variables were obtained from nationwide registries. We defined postdiagnosis use (two or more prescriptions) as a time-varying covariate with a one-year lag. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for CBC associated with nonaspirin NSAID use. During a median follow-up of 4.8 years (interquartile range: 2.3-9 years), 1,444 patients were diagnosed with CBC. Overall, postdiagnosis use of nonaspirin NSAID was associated with an adjusted HR for CBC of 0.98 (95% CI: 0.87-1.11). The HRs did not vary substantially with duration or intensity of nonaspirin NSAID use. Moreover, similar associations were found for COX-2 selective (HR: 1.02; 95% CI: 0.85-1.23) and nonselective (HR: 0.96; 95% CI: 0.82-1.13) nonaspirin NSAIDs. In conclusion, our nationwide cohort study of breast cancer patients does not suggest a reduced risk of CBC with nonaspirin NSAID use regardless of the COX-2 selectivity.

Original languageEnglish
JournalInternational Journal of Cancer
Volume144
Issue number6
Pages (from-to)1243-50
ISSN0020-7136
DOIs
Publication statusPublished - 2019

ID: 55905463